Q/C Technologies Inc QCLS

$0.75 -0.03 (-3.52%)

Valuation

Market cap
6,126,000
Revenue TTM
$0
Net income TTM
$-11,630,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
324,700
Avg volume
6,310,936
Day's range
$0.74 – $0.81
Shares out
8,190,000
Stochastic %K
2%
Beta
2.32
Analysts
Strong Buy
Price target
—

Price

Company profile

Q/C Technologies, Inc. operates as a clinical-stage pharmaceutical company. It operates through Pharmaceuticals and Computing Technology segments. The company develops Isomyosamine, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including sarcopenia, frailty, adverse effects of drugs used to treat diabetes and obesity, rheumatoid arthritis, and inflammatory bowe...

Show more

Q/C Technologies, Inc. operates as a clinical-stage pharmaceutical company. It operates through Pharmaceuticals and Computing Technology segments. The company develops Isomyosamine, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including sarcopenia, frailty, adverse effects of drugs used to treat diabetes and obesity, rheumatoid arthritis, and inflammatory bowel disease. It also develops Supera-CBD, a synthetic analog derivative of cannabidiol (CBD) to treat various conditions, including epilepsy, pain and anxiety/depression. In addition, it is involved in the development and eventual application of quantum computing technology, both for cryptocurrency applications;. The company was formerly known as TNF Pharmaceuticals, Inc. and changed its name to Q/C Technologies, Inc. in September 2025. The company was founded in 2014 and is headquartered in New York, New York.

Industry
Computer Hardware
Sector
Technology
Phone
856 848 8698
Website
https://www.qctechnologies.com
Address
1185 Avenue of the Americas, Suite 249, New York, United States

Latest news

Stocktwits

PostQCLSpaidlendinginfo Oct 2, 11:25 PM
$QCLS couple filings from tonight to pass along
0 replies
NoNameMeme Oct 2, 9:52 PM
$QCLS Don't worry fishies; it will be over $1 again after the next R/S. Q/C Technologies, Inc. (QCLS), formerly known as TNF Pharmaceuticals and Akers Biosciences, has a long history of aggressive reverse stock splits. | Sep 1, 2025 | 1-for-100 (0.01:1) Implemented right before rebranding to Q/C Technologies and pivoting to computing. | Feb 14, 2024 | 1-for-30 (0.0333333:1) Executed during its tenure as TNF Pharmaceuticals. | Apr 18, 2021 | 1-for-2 (0.5:1) Completed under its previous biosciences/pharmaceutical structures. | Nov 24, 2019 | 1-for-24 (0.04167:1) Corporate restructuring adjustment. | Nov 7, 2018 | 1-for-8 (0.125:1) Action taken to regain compliance with Nasdaq minimum bid requirements. | Nov 22, 2013 | 1-for-156 Executed ahead of its initial listing on the Nasdaq Capital Market.
0 replies
Charlie_wsb23 Oct 2, 9:01 PM
$QCLS What a mistake to have come here🤣
0 replies
CocaKolla Oct 2, 8:58 PM
$NAUT $QCLS
0 replies
Jojorida Oct 2, 6:53 PM
$QCLS 0.4
0 replies
focafoca99 Oct 1, 5:55 PM
$QCLS announced a research collaboration with Sandia National Labs to advance its optical AI processing unit. https://www.rapidticker.com/news/qcls-qc-technologies-announces-research-collaboration-268a5f
0 replies
Bcscoatings Oct 1, 4:53 PM
$NAMM $QCLS $GLND $GLDX.X
0 replies
Easttenn988 Oct 1, 4:21 PM
$QCLS nah gonna turn back G
0 replies